MedTrace Logo

Montelukast for Patients With Obstructive Sleep Apnea Syndrome

NCT03545997 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2021-02-17

No results posted yet for this study

Summary

This study compares the effect of Montelukast vs Placebo on Flow Mediated Dilatation of the Brachial Artery (FMD) in patients with obstructive sleep apnea syndrome.

Conditions

  • Sleep Apnea, Obstructive

Interventions

DRUG

Montelukast 10mg

The capsules will be presented in box of 95 capsules packaged in unit blister

DRUG

Placebo

Mannitol 350mg The capsules will be presented in box of 95 capsules packaged in unit blister

Sponsors & Collaborators

  • Act For Chronic Diseases

    collaborator OTHER

  • Direction Générale de l'Offre de Soins

    collaborator OTHER_GOV

  • University Hospital, Grenoble

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-29
Primary Completion
2020-03-20
Completion
2020-03-20

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03545997 on ClinicalTrials.gov